Sector ETF report for BBH
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Moderna has been rallying on the latest positive booster shot-related update.
Sector ETF report for BBH
In trading on Wednesday, shares of the Biotech ETF entered into oversold territory, changing hands as low as $150.5312 per share. We define oversold territory using the Relative Strength Index, or RSI,...
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.
Sector ETF report for BBH
The emergence of the Omicron variant of Covid-19 and inflationary pressure were key highlights of the broader market in November.
Moderna has been rallying amid concerns surrounding the omicron variant, which has led to possibilities of a rise in demand for COVID-19 vaccines and boosters.